We have

two reasons of this increase.

The better diagnosis, those cancers that are not misdiagnosed with adenocarcinomas, for instance, that are now diagnosed with well-neuroendocrine differentiation.

And also two other reasons.

One is the incidentalomas.

For any kind of scans that we are doing, we are detecting small tumors that usually have excellent, good prognosis.

And also the treatment that we have in advanced stage that is progressively increasing the prevalence of the disease.

course.

development.

But what needs for sure pay attention is that the movement of these drugs to the first line.

So this is the things that we have all in mind.

If this drug works in particular population, how this will work in combination with chemotherapy in first line setting.

So this is the data that we reported last year at NANETS and were recently updated at INETS a few months ago.

This is the phase one study, DIRON-7 study that evaluated the combination of chemotherapy, platinumen toposide plus obrixtamic.

And there were two cohorts.

and icons.

development.

But what needs for sure pay attention is that the movement of these drugs to the first line.

So this is the things that we have all in mind.

If this drug works in particular population, how this will work in combination with chemotherapy in first line setting.

So this is the data that we reported last year at NANETS and were recently updated at INETS a few months ago.

This is the phase one study, DIRON-7 study that evaluated the combination of chemotherapy, platinumen toposide plus obrixtamic.

And there were two cohorts.

and icons.

We have

two reasons of this increase.

The better diagnosis, those cancers that are not misdiagnosed with adenocarcinomas, for instance, that are now diagnosed with well-neuroendocrine differentiation.

And also two other reasons.

One is the incidentalomas.

For any kind of scans that we are doing, we are detecting small tumors that usually have excellent, good prognosis.

And also the treatment that we have in advanced stage that is progressively increasing the prevalence of the disease.

course.